Safety Analysis of Bevacizumab in Ovarian Cancer Patients

Bevacizumab (BEV) is beneficial for ovarian cancer patients, but the real world’s patient settings differ from those in clinical trials. This study tries to illustrate adverse events in the Taiwanese population. Patients with epithelial ovarian cancer treated with BEV at Kaohsiung Chang Gung Memoria...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yingwen, Lin, Hao, Ou, Yuche, Fu, Hungchun, Tsai, Chingchou, Chien, Chanchao Chang, Wu, Chenhsuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003828/
https://www.ncbi.nlm.nih.gov/pubmed/36902852
http://dx.doi.org/10.3390/jcm12052065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003828/
https://www.ncbi.nlm.nih.gov/pubmed/36902852
http://dx.doi.org/10.3390/jcm12052065

Ejemplares similares